Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.

Fasano S, Riccardi A, Messiniti V, Caramaschi P, Rosato E, Maurer B, Smith V, Siegert E, De Langhe E, Riccieri V, Airó P, Mihai C, Avouac J, Zanatta E, Walker UA, Iannone F, García De la Peña Lefebvre P, Distler JHW, Vacca A, Distler O, Kowal-Bielecka O, Allanore Y, Valentini G

Open source

DOI: 10.1136/annrheumdis-2019-215787
Published: 2019 Dec
Container: Annals of the rheumatic diseases
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/annrheumdis-2019-215787,
  title = {Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.},
  author = {Fasano S and Riccardi A and Messiniti V and Caramaschi P and Rosato E and Maurer B and Smith V and Siegert E and De Langhe E and Riccieri V and Airó P and Mihai C and Avouac J and Zanatta E and Walker UA and Iannone F and García De la Peña Lefebvre P and Distler JHW and Vacca A and Distler O and Kowal-Bielecka O and Allanore Y and Valentini G},
  year = {2019},
  journal = {Annals of the rheumatic diseases},
  doi = {10.1136/annrheumdis-2019-215787},
  url = {https://doi.org/10.1136/annrheumdis-2019-215787}
}

RIS

TY  - JOUR
TI  - Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.
AU  - Fasano S
AU  - Riccardi A
AU  - Messiniti V
AU  - Caramaschi P
AU  - Rosato E
AU  - Maurer B
AU  - Smith V
AU  - Siegert E
AU  - De Langhe E
AU  - Riccieri V
AU  - Airó P
AU  - Mihai C
AU  - Avouac J
AU  - Zanatta E
AU  - Walker UA
AU  - Iannone F
AU  - García De la Peña Lefebvre P
AU  - Distler JHW
AU  - Vacca A
AU  - Distler O
AU  - Kowal-Bielecka O
AU  - Allanore Y
AU  - Valentini G
PY  - 2019
JO  - Annals of the rheumatic diseases
DO  - 10.1136/annrheumdis-2019-215787
UR  - https://doi.org/10.1136/annrheumdis-2019-215787
ER  -

APA

S, F., A, R., V, M., P, C., E, R., B, M., V, S., E, S., E, D. L., V, R., P, A., C, M., J, A., E, Z., UA, W., F, I., P, G. D. L. P. L., JHW, D., A, V., O, D., O, K., Y, A., & G, V. (2019). Revised European Scleroderma Trials and Research Group Activity Index is the best predictor of short-term severity accrual.. Annals of the rheumatic diseases. https://doi.org/10.1136/annrheumdis-2019-215787

Source records

pubmed · retrieved 2026-09-26T08:08:58.198Z